Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13850677 | 0.78 | SLC6A4 (0.46) | MAPTKDM1AMAOAMAOB | |
| SCHEMBL14373087 | 0.70 | TP53 (1.00) | TP53MDM2MAPTALDH1A1HTT | |
| SCHEMBL3043200 | 0.69 | CHRNB2 (0.52) | TP53MDM2 | |
| SCHEMBL10635883 | 0.67 | MAPT (0.43) | MAPT | |
| SCHEMBL731775 | 0.67 | MAPT (0.54) | MAPT | |
| SCHEMBL28502868 | 0.66 | ALDH1A1 (0.72) | TP53MDM2MAPTCYP2A6ALDH1A1 | |
| SCHEMBL28503664 | 0.66 | ALDH1A1 (0.72) | TP53MDM2MAPTCYP2A6ALDH1A1 | |
| SCHEMBL29683884 | 0.66 | ALDH1A1 (0.72) | TP53MDM2MAPTCYP2A6ALDH1A1 | |
| SCHEMBL28508997 | 0.66 | ALDH1A1 (0.72) | TP53MDM2MAPTCYP2A6ALDH1A1 | |
| SCHEMBL6956567 | 0.66 | TP53 (0.54) | TP53MDM2MAPTALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-07 | — | — | US | disclosed |
| WO-2009058120-A1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SRI INTERNATIONAL (US) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118326-A1 | Nicotinic Acetylcholine Receptor Modulators | CHRNA10, CHRNA6, CHRNA5 | TP53 2482/4885MDM2 2759/4885MAPT 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.